MEK–ERK activation in breast cancer cell lines occurs after binding of oestrogen to its receptor (Collins and Webb, 1999), stimulation by insulin (Griffiths et al, 1998) or binding of growth factors like EGF or PDGF (Whitmarsh and Davis, 1996). The gene discussed is MAP2K7; the disease is breast cancer.